Evinacumab
Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody) . Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia[1].
Product Specifications
CAS Number
1446419-85-7
Product Name Alternative
REGN1500
UNSPSC
12352203
Target
ANGPTL
Type
Inhibitory Antibodies
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/evinacumab.html
Purity
99.24
Solubility
10 mM in DMSO
Smiles
[Evinacumab]
Molecular Weight
(144.5 kDa)
References & Citations
[1]Gusarova V, et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J Lipid Res. 2015 Jul;56 (7) :1308-17.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
orb3005975-01 20 µg
Recombinant Human Probable non-functional immunoglobulin lambda variable 1-50 (LV150), Biotinylated
Sign In for Pricing
View Details orb3005975-02 100 µg
Recombinant Human Probable non-functional immunoglobulin lambda variable 1-50 (LV150), Biotinylated
Sign In for Pricing
View Details orb3005975-03 1 mg
Recombinant Human Probable non-functional immunoglobulin lambda variable 1-50 (LV150), Biotinylated
Sign In for Pricing
View Details 